GlassScriptPhysician profile
Frederick P Marquinez
NPI 1114913258
$1,133.51
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $146 · 2021: $338 · 2022: $142 · 2023: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $213.70 | 2019-2023 | Ninlaro |
| Incyte Corporation | $98.33 | 2020-2023 | Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $92.72 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $87.78 | 2021-2023 | |
| Lilly USA, LLC | $72.46 | 2019-2021 | |
| Pfizer INC. | $68.29 | 2021-2023 | |
| Glaxosmithkline, LLC. | $67.38 | 2021-2022 | |
| Seagen INC. | $64.84 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $53.69 | 2021-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $53.52 | 2020-2023 | |
| Amgen INC. | $44.10 | 2022-2023 | Kyprolis, Blincyto |
| Genentech USA, INC. | $27.91 | 2019 | |
| Daiichi Sankyo INC. | $24.04 | 2020-2021 | |
| Astellas Pharma US INC | $23.24 | 2021 | |
| Celgene Corporation | $21.75 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $21.48 | 2021 | |
| Epizyme, INC. | $18.00 | 2021 | |
| Kite Pharma, INC. | $17.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.39 | 2023 | |
| Merck Sharp & Dohme LLC | $16.71 | 2021 | |
| Aveo Pharmaceuticals, INC. | $16.36 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Marquinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.